Skip to main content

Treats Adults

Daniel E Soffer, MD

Cardiologist, Interventional Cardiologist

Rated 4.8 out of 5 stars
Photo of Daniel E Soffer

Research at a glance

Top areas of exploration

  • Platelet Aggregation Inhibitors , 14 publications
  • Clopidogrel , 11 publications
  • Ticagrelor , 10 publications
  • Platelet Aggregation , 8 publications

Research activity

44 publications

1,385 citations

Why is this important?

Active clinical trials

My publications

44 publications

2024

Clopidogrel-Mediated P2Y12 Inhibition According to Renal Function in Patients With Diabetes Mellitus and CAD.

JACC. Basic to translational science

PubMed • Publisher's site

2024

P2Y12 Inhibition in Patients Requiring Oral Anticoagulation After Percutaneous Coronary Intervention: The SWAP-AC-2 Study.

JACC. Cardiovascular interventions

PubMed • Publisher's site

2024

Switching from Dual Antiplatelet Therapy with Aspirin Plus a P2Y12 Inhibitor to Dual Pathway Inhibition with Aspirin Plus Vascular-Dose Rivaroxaban: The Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) Study.

Thrombosis and haemostasis

PubMed • Publisher's site

2023

Switching From Cangrelor to Prasugrel in Patients Undergoing Percutaneous Coronary Intervention: The Switching Antiplatelet-6 (SWAP-6) Study.

JACC. Cardiovascular interventions

PubMed • Publisher's site

2023

Impact of evolocumab on the pharmacodynamic profiles of clopidogrel in patients with atherosclerotic cardiovascular disease: a randomised, double-blind, placebo-controlled study.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology

PubMed • Publisher's site